SynthesisFrontiers in endocrinology2022
Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis.
Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Ovarian Neuroendocrine Neoplasms: Challenges and Future Perspectives.Journal of clinical medicine · 2025Review
- Morphological and Immunohistochemical Support for the Origin of the Carcinoid Component in Strumal Carcinoids: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical, pathological characteristics, and therapeutic outcomes of primary ovarian carcinoid tumors: a case series of 15 cases.World journal of surgical oncology · 2025Article
- A rare case report of primary ovarian carcinoid presenting with constipation.Frontiers in oncology · 2025Article
- Clinicopathological and imaging features of struma ovarii: a retrospective study.Frontiers in oncology · 2025Article
- Case Report: Strumal carcinoid tumor in the ovary: report of a rare occurrence with a review of literature.Frontiers in medicine · 2025Article
- Diagnostic and therapeutic challenges of a rare large ovarian strumal carcinoid in pregnancy, about a case report.International journal of surgery case reports · 2024Article
- Incidence, clinical characteristics, and survival outcomes of ovarian strumal diseases: a retrospective cohort study.BMC women's health · 2023Article
- Strumal Carcinoid Tumor of the Ovary: Report of Rare Occurrence with Review of Literature.Diagnostics (Basel, Switzerland) · 2022Article
- Conservative treatment of borderline ovarian tumors: a retrospective study.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian strumal carcinoid is a rare tumor in which thyroid (struma) and carcinoid components coexist. The disease is generally considered to be a borderline malignancy, however, cases with metastatic disease have been described. No data in the literature are available to guide diagnosis and therapy. Methods: We performed a pooled analysis and a systematic review of histopathological-confirmed strumal carcinoid cases published in the literature using the following keywords: "strumal carcinoid of the ovary", "strumal carcinoid case report". A case of strumal carcinoid tumor diagnosed and followed-up at the Medical Oncology Unit of Spedali Civili (Brescia, Italy) was also described and included. Results: Sixty-six eligible publications were identified, providing data from one hundred and seventeen patients, plus a case diagnosed at our institution. At presentation, among the eighty-eight patients with symptomatic disease, 37% of patients suffered from abdominal distention and 49% from pain due to a growing abdominal tumor mass, 37% from constipation (peptide YY was analyzed in only nine of them, resulting above the physiologic range). Surgery was the primary therapy in 99% of the patients. Three patients had metastatic disease at diagnosis and five patients underwent recurrence after radical surgery. Histology at disease recurrence concerned the thyroid component in two patients, the carcinoid component in two patients, both histologies in one patient. Median disease-free survival and overall survival in this series were not attained. Conclusion: Strumal carcinoid of the ovary generally presents a benign behavior and surgery is curative in most cases. However, a small group of patients with this disease can undergo disease recurrence due to both the thyroid and the neuroendocrine (carcinoid) components. A follow-up in radically operated patients is therefore needed, particularly in those with a voluminous disease at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.